Adherence to the National Guidelines for Follow-Up Protocol in Subjects with Type 2 Diabetes Mellitus in Greece: The GLA
- PDF / 875,295 Bytes
- 22 Pages / 595.276 x 790.866 pts Page_size
- 33 Downloads / 187 Views
ORIGINAL RESEARCH
Adherence to the National Guidelines for Follow-Up Protocol in Subjects with Type 2 Diabetes Mellitus in Greece: The GLANCE Study Nikolaos Papanas
. Moses Elisaf . Kalliopi Kotsa . Andreas Melidonis .
Stavros Bousboulas . Alexandra Bargiota . Emmanouel Pagkalos . John Doupis . Ioannis Ioannidis . Iakovos Avramidis . Angelos C. Pappas . Gerasimos Karousos . Eleni Arvaniti . Magdalini Bristianou . Katerina Pietri . Eugenia Karamousouli . Bernd Voss . Ilias Migdalis . Nikolaos Tentolouris Received: July 22, 2020 / Accepted: September 19, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Physician adherence, or lack therefore, to diabetes care and follow-up guidelines may be linked to the rates of achieving suboptimal glycaemic, blood pressure and lipid targets in people with type 2 diabetes mellitus (T2DM). In this cross-sectional study Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12967595.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s13300020-00935-6) contains supplementary material, which is available to authorized users. N. Papanas (&) Diabetes Centre, Second Department of Internal Medicine, University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece e-mail: [email protected]
we evaluated physician adherence to the patient follow-up protocol (PFP) of the 2017 Hellenic Diabetes Association (HDA) guidelines and also assessed glycated haemoglobin (HbA1c), blood pressure and lipid control achievement rates in the routine care setting in Greece. Methods: Eligible subjects were adults with T2DM receiving oral hypoglycaemic agents (OHAs) for C 1 year who had C 2 HbA1c measurements in the previous year and an HbA1c target \ 7%. Overall adherence at the subject level was defined as the percentage of the 62 HDA PFP items that had been met during the past year. A. Melidonis Diabetes Centre, General Hospital ‘‘Tzanio’’, Piraeus, Greece S. Bousboulas Diabetes Centre, General Hospital ‘‘Agios Panteleimon’’, Piraeus, Greece
M. Elisaf Department of Internal Medicine, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece
A. Bargiota Department of Endocrinology and Metabolic Diseases, University Hospital of Larissa, Thessaly, Greece
K. Kotsa Division of Endocrinology and Metabolism–Diabetes Centre, First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
E. Pagkalos Diabetes Department, Clinic ‘‘Thermi’’, Thessaloniki, Greece
Diabetes Ther
Results: Between June and December 2018, 601 eligible subjects (54.6% men; mean age 65.2 years; median T2DM duration 5.9 years, of whom 96.5% had C 1 medical condition/comorbidity), were enrolled into the study by 53 hospital- and office-based endocrinologists, internists and general practitioners. The main OHAs prescribed at enrolment were metformin (91.0%), dipeptidyl peptidase-4 inhibitors (60
Data Loading...
